Atara Biotherapeutics, Inc. (ATRA) intrinsic value & 10-year financials
Atara Biotherapeutics, Inc. (ATRA) has a Graham intrinsic value of $85.36 per share. At $9.18 on Oct 17, 2026, the stock trades 89% below that value. Over the last 10 fiscal years revenue grew 23.9% a year to $120.8M, with an average return on invested capital of -634.5%.
- Graham intrinsic value
- $85.36
- Share price (Oct 17, 2026)
- $9.18
- Price vs Graham value
- 89% below
- Market cap
- $116.8M
- Revenue (FY2025)
- $120.8M
- Revenue growth (10-yr CAGR)
- 23.9%
- ROIC (10-yr avg)
- -634.5%
- Free cash flow (FY2025)
- —
ATRA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $120.8M | $32.7M | $2.57 | — | 29.7% | -55.1% |
| FY2024 | $128.9M | -$85.4M | -$11.41 | -$69.0M | -64.7% | 97.1% |
| FY2023 | $8.6M | -$276.1M | -$2.61 | -$194.2M | -3219.5% | -4457.8% |
| FY2022 | $63.6M | -$228.3M | -$2.24 | -$274.6M | -441.2% | -192.9% |
| FY2021 | — | -$340.1M | -$3.63 | -$231.1M | — | -143.6% |
| FY2020 | — | -$306.6M | -$4.15 | -$185.3M | — | -122.2% |
| FY2019 | — | -$291.0M | — | -$241.4M | — | -116.2% |
| FY2018 | — | -$230.7M | — | -$215.7M | — | -85.2% |
| FY2017 | — | -$119.5M | — | -$107.7M | — | — |
| FY2016 | — | -$79.0M | — | -$63.0M | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Atara Biotherapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Atara Biotherapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -59.0% ROIC.
Atara Biotherapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Atara Biotherapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $85.36 per share.